---
aliases: [BSX]
---
#actor #healthcare #medtech #usa #public

**Boston Scientific** (NYSE: BSX) — Medical device company focused on interventional cardiology, electrophysiology, and neuromodulation. Fastest-growing large-cap medtech with 20%+ revenue growth.

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | BSX |
| Market cap | ~$141B (Jan 2026) |
| Revenue (TTM) | ~$19.4B |
| Revenue growth | +22% YoY |
| Founded | 1979 |
| HQ | Marlborough, Massachusetts |

---

## Why Boston Scientific matters

**Growth leader in medtech.** While [[Medtronic]] and [[Abbott]] grow mid-single digits, Boston Scientific has delivered 18%+ CAGR in market cap over 5 years. The company's focused portfolio in high-growth interventional markets is outperforming diversified peers.

**EP/ablation strength.** Boston Scientific's FARAPULSE pulsed field ablation system was first-to-market in the US (2024) and is driving share gains against [[Medtronic]] and [[Abbott]].

---

## Business segments

| Segment | Products | Dynamics |
|---------|----------|----------|
| **Cardiovascular** | Stents, structural heart, EP | Core growth driver |
| **MedSurg** | Endoscopy, urology | Stable |
| **Neuromodulation** | Spinal cord stimulation, DBS | Competitive |

---

## Key products

| Product | Category | Status |
|---------|----------|--------|
| **FARAPULSE** | Pulsed field ablation | First-to-market US, rapid adoption |
| **WATCHMAN FLX** | Left atrial appendage closure | Stroke prevention leader |
| **ACURATE neo2** | Aortic valve | Structural heart growth |
| **WaveWriter Alpha** | Spinal cord stimulator | Pain management |

---

## Financials

| Year | Revenue | Growth | Notes |
|------|---------|--------|-------|
| 2023 | $14.2B | +12% | |
| 2024 | $16.7B | +18% | |
| 2025E | ~$20B | +20% | Q3 2025: $5.1B (+20%) |

Revenue has nearly doubled from $11.9B in 2020.

---

## Investment considerations

**Bull case:**
- FARAPULSE driving EP market share gains
- WATCHMAN structural heart growth continues
- Premium growth multiple deserved
- M&A optionality

**Bear case:**
- Valuation stretched (~40x earnings)
- [[Medtronic]] and [[Abbott]] launching competitive PFA
- Neuromodulation competitive pressure
- Market expecting perfection

---

## Related

- [[Healthcare]] — sector hub
- [[Medtronic]] — primary competitor
- [[Abbott]] — EP/device competitor
- [[Intuitive Surgical]] — surgical robotics comparison

---

*Created 2026-01-28*
